Home / About us
As a leading research-driven pharmaceutical and biotechnology company, Laurus Labs aims to improve the quality of life for millions around the world

We develop innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality and affordability. We work with all the top 10 generic pharmaceutical companies in the world. We sell our APIs in 56 countries. Our major focus areas include anti-retroviral, Hepatitis C and Oncology drugs.

Continuous innovation is the lifeblood of our business. Therefore, undertake dedicated R&D in areas that have significant growth potential. We filed 322 patents in which we own 203 patents. We have commercialised 60+ products since inception across three distinct business units: Generics API, Generics FDF and Synthesis.

As a company, we conduct our business with utmost transparency and integrity. This helps us attract the best talent and win the trust of our stakeholders. Given that we operate in a highly regulated sector, we adopt a high-watermark approach to compliance to ensure that we exceed the requirements of all applicable international standards.

Annual Report

We are making great progress on our strategic goals. See our latest annual report.

Discover more about Laurus Labs

We are a science-led company at our core. We push back the frontiers of science to serve the needs of humanity. Our state-of-the-art research labs enable us to produce new cures to some of the most challenging diseases. With our manufacturing facilities, we cracked the code of creating high-quality and affordable medicines. Our facilities have been certified and approved by WHO, USFDA, NIP Hungary, PMDA, KFDA and BfArM. Our strong R&D and API manufacturing capabilities are enabling us to grow rapidly. We are also one of the most-admired companies to work for in the pharmaceutical and biotechnology sector.

  • 2006

    Set up our R&D Centre at IKP, Knowledge Park, Hyderabad

    Signed a term sheet with a leading Indian pharmaceutical company for oncology APIs

    Filed our first patent application

  • 2007

    Set up API manufacturing facility Unit-I at Visakhapatnam

    Secured investment from Aptuit Singapore of INR 1.02 billion

    Executed manufacturing and services agreements with three multinational companies

    Commenced operations at our R&D Centre

  • 2008

    Filed our first-ever Drug Master File

    Commenced operations at Unit-I

    Supplied company’s first product to the US

  • 2009

    DSIR recognised our R&D Centre

    Commercialised four nutritional fine chemicals

    Launched first product in Europe

    Entered into a license agreement with an international organisation and a multinational company to manufacture and sell our products in the ARV segment

  • 2010

    Received USFDA, TGA and UK MHRA certification for the Unit 1, Vishakhapatnam

  • 2011

    Received USFDA and KFDA certification for our R&D Centre

    Received KFDA certification for Unit 1

  • 2012

    Secured investment of INR 490 million from FIL Capital Management and FIP through primary investment and

    Secondary acquisition of Aptuit’s majority stake along with additional investments by one of our promoters

  • 2013

    Crossed INR 10 billion in revenues

    Received WHO approval for Unit-I

  • 2014

    Acquired 135 acres in Visakhapatnam for expansion

    Received an investment of INR 3000 million from Bluewater

    Commenced construction of Unit 2

    Incorporated Laurus Inc. in Delaware, US as a wholly-owned subsidiary

  • 2015

    Commenced commercial operations at Unit 3, Visakhapatnam

    Acquired 27% stake in Sriam Labs Private Limited, Hyderabad

    Successful inspection by WHO, NIP Hungary and US FDA for Unit 1 and Unit 3 manufacturing sites

  • 2016

    Successful USFDA inspection of the kilo-lab facility at our R&D Centre

    Received approval from BfArM Germany for Unit 2 at Vishakhapatnam

    Crossed INR 15 billion in revenues

    Filed first ANDA with the USFDA and first dossier with the WHO

  • 2017

    Successful USFDA inspection of Unit 1, 2 & 3 API manufacturing facilities with no critical observations. (Unit 2 has no 483 observations)

    Successful WHO inspection of Units 1, 2 & 3

    Successful BGV Hamburg (German Regulatory Authority) inspection of Unit 2 (FDF) with no critical or major observations

  • 2018

    Crossed INR 20 billion of revenue. Commenced commercial operations from Unit 4.

    Incorporated a subsidiary in Germany.

    Unit 2-Formulations, inspected by USFDA with Zero 483 observations.

    Launched maiden FDF product Tenofovir in USA, Canada and emerging markets.

    Certified as Great Place to Work for the year 2018.

  • 2019

    Unit 6 – EIR Received from USFDA

    Entered into Strategic partnership with Global Fund for 3.5 years.

    Executed a major tender order and delivered ahead of schedule

    Executed highest on-time delivery in FDF orders.

    Maiden EIR received for Unit 4

  • 2020

    Incorporated Laurus Synthesis Pvt. Ltd

    Acquired assets of an API Unit in Vizag

    Acquired Aspen’s South Africa Subsidiary – Laurus Generics SA(PTY) Limited

  • 2021

    Incorporated Laurus Ingredients Pvt. Ltd. A Wholly Owned step down subsidiary of Laurus Synthesis Pvt. Ltd.

    Acquisition of 72.55% stake in Richcore Life Sciences Pvt Ltd (Laurus Bio)

    Laurus Labs acquires substantial minority stake in a CAR-T cell therapy company - ImmunoACT

  • 2022

    Crossed INR 48 billion of revenue

    Incorporated Laurus Synthesis Pvt. Ltd & acquired assets of an API Unit in Vizag

    Acquired Aspen’s South Africa Subsidiary – Laurus Generics SA(PTY) Limited

    Laurus Synthesis Inc USA is merged with Laurus Generics Inc USA.

    Crossed INR 16 billion FDF Sales

Our keys indcies


State-of-the-art R & D labs in India and the US


APIs manufactured at 9 manufacturing facilities


Million in annual revenues in FY22


Research scientists out of a total workforce of over 5000


Customers across 56 countries


Patents filed and 203 patents granted


Million liters of reactor capacity


Manufacturing Facilities